Abstract Objectives The 2019 American Society of Colposcopy and Cervical Pathology
management guidelines recommend that patients with an unsatisfactory Papanicolaou …

BACKGROUND Because of cervical cancer screening recommendations and forthcoming
first‐line human papillomavirus (HPV) screening, many Papanicolaou (Pap) tests will be …

Cervical screening with combined cytology and high-risk human papillomavirus (HR-HPV)
detection has been approved for women 30 years or older. We investigated the clinical use …

BACKGROUND To the authors' knowledge, few studies to date have examined adherence
to recommended guidelines for follow‐up and outcomes after an unsatisfactory …

Objective Current US guidelines for cotesting recommend that the large numbers of women
who test Pap-negative, but human papillomavirus (HPV)–positive, return in 1 year, and …

Introduction In the past 2 decades, cervical cancer screening guidelines in the United States
have undergone numerous revisions with recent greater emphasis on primary high-risk …

Background High‐risk human papillomavirus (HPV)–Papanicolaou (Pap) cotesting is
recommended for cervical cancer screening in women aged≥ 30 years. The current study …

In 2009, the Cytopathology Education and Technology Consortium issued a statement on
human papillomavirus (HPV) DNA test utilization that was published in multiple journals. 1 …

BACKGROUND Different US practice guidelines have conflicting recommendations for
when women should return after a screening result of human papillomavirus (HPV) …

Introduction Although the rates are generally low (0.2%-10%), unsatisfactory Papanicolaou
(Pap) tests are associated with an increased risk of epithelial lesions on subsequent follow …